Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study

Ueno, Hideki; Ioka, Tatsuya; Ikeda, Masafumi; Ohkawa, Shinichi; Yanagimoto, Hiroaki; Boku, Narikazu; Fukutomi, Akira; Sugimori, Kazuya; Baba, Hideo; Yamao, Kenji; Shimamura, T; Sho, Masayuki; Kitano, Masayuki; Cheng, Ann‐Lii; Mizumoto, Kazuhiro; Chen, Jen Shi; Furuse, Junji; Funakoshi, Akihiro; Hatori, Takashi; Yamaguchi, Taketo; Egawa, Shinichi; Satō, Atsushi; Ohashi, Yasuo; Okusaka, Takuji; Tanaka, Masao

doi:10.1200/jco.2012.43.3680

Cited by 545 publications

(439 citation statements)

References 26 publications

Supporting

Mentioning

419

Contrasting

Unclassified

Order By: Relevance

“…[22] A 2013 phase III study by Ueno et al studied a newer oral fluoropyrimidine derivative called S-1. [23] This study showed S-1 to be non-inferior to gemcitabine. The study also tried to establish superiority of gemcitabine and S-1 to gemcitabine alone but failed to do so with statistical significance.…”

Section: Established Risk Factors and High Risk Of Recurrencementioning

confidence: 92%

Emerging therapies for pancreatic ductal carcinoma

Falcone

Davis

Stain

et al. 2016

JST

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is a solid tumor mass that grows and metastasizes rapidly. There are no definitive methods for early detection and most patients are diagnosed at a late stage. Those diagnosed at an early stage are eligible for tumor resection. However, many of these patients are soon burdened with tumor recurrence. The tumor grows back aggressively and with resistance to the original chemotherapy. Gemcitabine has been the treatment of choice, but provides only minimal survival prolongation. Researchers are trying to improve the current standard of care by finding different methods to improve treatment efficacy and reduce side effects. This review emphasizes recent data on targeting the tumor using antifibrotic, nanotargeted, and dendritic cell therapies. Antifibrotic therapy aims to reduce tumor fibrosis, which prevents adequate chemotherapy penetration. Nanotargeted therapy offers precise targeting of cancer cells and chemotherapy delivery. Dendritic cell vaccines stimulate the body's immune system to target PDAC cells. These three treatment methods or a combination of them might improve the lifespan and quality of life for PDAC patients.

show abstract

Section: Established Risk Factors and High Risk Of Recurrencementioning

confidence: 92%

Emerging therapies for pancreatic ductal carcinoma

Falcone

Davis

Stain

et al. 2016

JST

View full text Add to dashboard Cite

show abstract

“…Combination therapy was selected as first‐line chemotherapy because of its high response rate in patients with pancreas cancer 9. At the same time, an accurate pathologic diagnosis was made from tumor specimens and she was diagnosed with FDCS.…”

Section: Case Reportmentioning

confidence: 99%

Follicular dendritic cell sarcoma treated with a variety of chemotherapy

Sasaki

Izumi

Yokoyama

et al. 2016

Hematological Oncology

View full text Add to dashboard Cite

Follicular dendritic cell sarcoma (FDCS) is a very rare malignant tumor derived from follicular dendritic cells. Radical resection is the standard therapy for patients with local disease, but an optimal chemotherapy regimen has not been determined for unresectable disease. We report our experience of an FDCS patient with multiorgan involvement. In the present case, disease was only located in the pancreas initially and radical resection was performed. Multiple metastasis developed after the treatment and several factors that indicated a poor prognosis were observed. The present case had a very poor prognostic disease but survived for a long time with a good performance status because of the multiple chemotherapy regimens, which follow therapeutic strategies for malignant lymphoma and soft tissue sarcoma. As far as we know, this is the first study reporting the indication of bendamustine for FDCS patients.

show abstract

“…There is some interest that SPARC (secreted protein rich in cysteine) testing may select patients who may benefit from Nab Paclitaxel. [62,74] Table 4 shows the results of some key studies in first-line metastatic pancreatic cancer [3,60,61,66,69,72,75,76].…”

Section: Metastatic Disease -First Line Therapymentioning

confidence: 99%